LncRNA UCA1 Induces Acquired Resistance to Gefitinib by Epigenetically Silencing CDKN1A Expression in Non-small-Cell Lung Cancer

Lung cancer is the most common cancer globally and is associated with high morbidity and mortality. Gefitinib has been widely used for treating advanced non-small-cell lung cancer (NSCLC). However, acquired resistance usually develops, although we still know little about the mechanism underlying thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Tianwei, Yan, Shuai, Wang, Mengwei, Jiang, Lihua, Ma, Pei, Lu, Binbin, Chen, Qinnan, Wei, Chenchen, Wang, Zhaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235350/
https://www.ncbi.nlm.nih.gov/pubmed/32477939
http://dx.doi.org/10.3389/fonc.2020.00656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235350/
https://www.ncbi.nlm.nih.gov/pubmed/32477939
http://dx.doi.org/10.3389/fonc.2020.00656

Ejemplares similares